Shahed University Daneshvar Medicine 2716-9723 20 4 2012 10 22 Comparison of clinical response to Zataria multiflora vaginal cream and boric acid in patients with recurrent vulvovaginal candidiasis Comparison of clinical response to Zataria multiflora vaginal cream and boric acid in patients with recurrent vulvovaginal candidiasis 35 42 1546 FA Maryam Rabiei 0000-0002-7487-7863 Hossein Akbari Mohsen Naseri Reza Bekhradi Maryam Nikzad Farahnaz Torkestani Journal Article 2020 09 26  Background and Objective: Since long-term therapy of recurrent vulvovaginal candidiasis patients with azol is accompanied with drug resistance and systemic toxicity, thus, researches have returned to non-azole drugs. This research compared clinical response of these patients to boric acid and leukorex (Zataria multiflora). Materials and Methods: This study was performed as a blind clinical trial in control with positive cases (parallel). Patients with recurrent vulvovaginal candidiasis that had a positive culture without any predisposing factors were enrolled in this survey. Vaginal cream of Zataria multiflora 1% and boric acid 3% were given blindly. Signs and symptoms on first visit, and 1 and 6 months after starting treatment was analyzed using chi square, Mann-Whitney and t tests. Results: In boric acid group, the score of severity signs initially was 9±3.3 that got to 3.48±3.8 and 3.33±5.1 in first and second periods of therapy, respectively. In Zataria multiflora group, the score of severity signs initially was 8.21±3.6 that got to 2.52±2.46 and 3.36±3.7 in first and second periods of therapy, respectively. The reduced scores of two groups were significant (p < /001). The final cure rate was 74/2% and 64/5% in boric acid and Zataria multiflora groups, respectively that there was not a significant difference between the two groups. Conclusion: Zataria multiflora is considers as an alternative drug in treatment of patients with recurrent vulvovaginal candidiasis.   Background and Objective: Since long-term therapy of recurrent vulvovaginal candidiasis patients with azol is accompanied with drug resistance and systemic toxicity, thus, researches have returned to non-azole drugs. This research compared clinical response of these patients to boric acid and leukorex (Zataria multiflora). Materials and Methods: This study was performed as a blind clinical trial in control with positive cases (parallel). Patients with recurrent vulvovaginal candidiasis that had a positive culture without any predisposing factors were enrolled in this survey. Vaginal cream of Zataria multiflora 1% and boric acid 3% were given blindly. Signs and symptoms on first visit, and 1 and 6 months after starting treatment was analyzed using chi square, Mann-Whitney and t tests. Results: In boric acid group, the score of severity signs initially was 9±3.3 that got to 3.48±3.8 and 3.33±5.1 in first and second periods of therapy, respectively. In Zataria multiflora group, the score of severity signs initially was 8.21±3.6 that got to 2.52±2.46 and 3.36±3.7 in first and second periods of therapy, respectively. The reduced scores of two groups were significant (p < /001). The final cure rate was 74/2% and 64/5% in boric acid and Zataria multiflora groups, respectively that there was not a significant difference between the two groups. Conclusion: Zataria multiflora is considers as an alternative drug in treatment of patients with recurrent vulvovaginal candidiasis.  https://daneshvarmed.shahed.ac.ir/article_1546_1af15ae5429f7c15724f12b1139038b7.pdf